Payment overview · 2025
General Payments
$515.77
22 reported records · 6 companies
Healthcare provider profile · identity verified
Sergey Vassilevich, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · STATEN ISLAND, NY · NPI 1346962776
Verified facts
What the public records show
CMS Open Payments records show Sergey Vassilevich, NP received $515.77 in general payments during 2025 across 22 reported records.
ABBVIE INC. accounted for 22.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Linzess, Qulipta, Ubrelvy, Xifaxan, Ztlido.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 265 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Ubrelvy by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Ztlido by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $113.62 | 22.0% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $103.73 | 20.1% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $103.41 | 20.1% | 6 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $93.26 | 18.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $82.94 | 16.1% | 3 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $18.81 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $515.77 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $103.73 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $103.41 | 6 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $93.26 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $82.94 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $81.10 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $68.52 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $24.75 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.80 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 265 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 20 | exact normalized | Medicare Part D |
| ZTLido ztlido |
2025 | Ztlido | 2024 | 94 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
265 | 36 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
94 | 13 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
20 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Diclofenac Sodium | Diclofenac Sodium | 338 | 48 |
| Linzess | Linaclotide | 265 | 36 |
| Zenpep | Lipase/Protease/Amylase | 234 | 30 |
| Vascepa | Icosapent Ethyl | 222 | 32 |
| Myrbetriq | Mirabegron | 192 | 22 |
| Metformin Hcl | Metformin Hcl | 172 | 29 |
| Atorvastatin Calcium | Atorvastatin Calcium | 165 | 29 |
| Gabapentin | Gabapentin | 142 | 25 |
| Ezetimibe | Ezetimibe | 135 | 24 |
| Amlodipine Besylate | Amlodipine Besylate | 133 | 23 |
| Eliquis | Apixaban | 120 | 15 |
| Restasis | Cyclosporine | 98 | 13 |
| Losartan Potassium | Losartan Potassium | 95 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 95 | 16 |
| Ztlido | Lidocaine | 94 | 13 |
| Nurtec Odt | Rimegepant Sulfate | 87 | 15 |
| Meclizine Hcl | Meclizine Hcl | 86 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 85 | 12 |
| Famotidine | Famotidine | 84 | 18 |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 78 | suppressed |
| Ozempic | Semaglutide | 77 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 73 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 73 | 17 |
| Ibuprofen | Ibuprofen | 69 | 19 |
| Clonidine Hcl | Clonidine Hcl | 67 | suppressed |
| Allopurinol | Allopurinol | 65 | suppressed |
| Dexilant | Dexlansoprazole | 65 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | suppressed |
| Memantine Hcl | Memantine Hcl | 61 | 13 |
| Furosemide | Furosemide | 59 | 14 |
| Memantine Hcl Er | Memantine Hcl | 59 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 56 | 11 |
| Omeprazole | Omeprazole | 54 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | 12 |
| Lidocaine | Lidocaine | 52 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 51 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 51 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 50 | 11 |
| Mounjaro | Tirzepatide | 50 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 50 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 50 | suppressed |
| Azithromycin | Azithromycin | 49 | 33 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 49 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 49 | suppressed |
| Jublia | Efinaconazole | 47 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 43 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 43 | 11 |
| Levothyroxine Sodium | Levothyroxine Sodium | 42 | suppressed |
| Lisinopril | Lisinopril | 42 | suppressed |
| Simvastatin | Simvastatin | 42 | suppressed |
| Atenolol | Atenolol | 40 | suppressed |
| Rivastigmine | Rivastigmine | 39 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 38 | suppressed |
| Valsartan | Valsartan | 37 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 36 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 36 | 13 |
| Bystolic | Nebivolol Hcl | 35 | suppressed |
| Uloric | Febuxostat | 35 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 35 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 34 | suppressed |
| Jardiance | Empagliflozin | 34 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 33 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Cyclosporine | Cyclosporine | 30 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 30 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Ubrelvy | Ubrogepant | 29 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Xiidra | Lifitegrast | 27 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 26 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 25 | suppressed |
| Ciclopirox | Ciclopirox | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | suppressed |
| Livalo | Pitavastatin Calcium | 25 | suppressed |
| Creon | Lipase/Protease/Amylase | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Mesalamine | Mesalamine | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 23 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 14 |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 21 | suppressed |
| Meloxicam | Meloxicam | 21 | suppressed |
| Crestor | Rosuvastatin Calcium | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Xifaxan | Rifaximin | 20 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Tavaborole | Tavaborole | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 12 |
| Celecoxib | Celecoxib | 18 | suppressed |
| Edarbi | Azilsartan Medoxomil | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 15 |
| Baclofen | Baclofen | 16 | suppressed |
| Nexium | Esomeprazole Magnesium | 16 | suppressed |
| Nicotrol Ns | Nicotine | 16 | suppressed |
| Qulipta | Atogepant | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 13 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 13 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 13 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Benicar | Olmesartan Medoxomil | 12 | suppressed |
| Carvedilol | Carvedilol | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Lialda | Mesalamine | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Ongentys | Opicapone | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Qbrexza | Glycopyrronium Tosylate | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $515.77 · 22 records | ABBVIE INC. | CREON, IBSRELA, LINZESS, OTEZLA, QULIPTA, REPATHA, Symbravo, UBRELVY, XIFAXAN, ZTLido | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error